Anzeige
Meldung des Tages: Freitagabend nachbörslich veröffentlicht – was der Markt erst am Montag sieht
Werbung
Attraktive Knock-Outs auf Regeneron Pharmaceuticals Inc
Typ Hebel Bid / Ask WKN
Call
4,3 14,54 € / 14,64 €
FD3HRZ
Typ Hebel Bid / Ask WKN
Put
6,2 10,08 € / 10,18 €
SY4NL1
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Aktie News

Aktie
WKN:  881535 ISIN:  US75886F1075 US-Symbol:  REGN Branche:  Biotechnologie Land:  USA
742,01 $
-7,43 $
-0,99%
626,14 € 30.01.26
Depot/Watchlist
Marktkapitalisierung *
68,87 Mrd. €
Streubesitz
7,83%
KGV
18,37
Dividende
3,52 $
Dividendenrendite
0,46%
neu: Nachhaltigkeits-Score
62 %
Index-Zuordnung
Nasdaq 100
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,40: VJ2H6D
Werbung

Regeneron Pharmaceuticals News

04.02.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
04.02.25 - PR Newswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
03.02.25 - PR Newswire
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN PR Newswire
31.01.25 - PR Newswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire
31.01.25 - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
31.01.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN PR Newswire

Newssuche

Videos

newspaper
29.01.26 -10,12%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »